Unsupervised domain adaptation for mobile semantic segmentation based on cycle consistency and feature alignment

The supervised training of deep networks for semantic segmentation requires a huge amount of labeled real world data. To solve this issue, a commonly exploited workaround is to use synthetic data for training, but deep networks show a critical performance drop when analyzing data with slightly different statistical properties with respect to the training set. In this work, we propose a novel Unsupervised Domain Adaptation (UDA) strategy to address the domain shift issue between real world and synthetic representations. An adversarial model, based on the cycle consistency framework, performs the mapping between the synthetic and real domain. The data is then fed to a MobileNet-v2 architecture that performs the semantic segmentation task. An additional couple of discriminators, working at the feature level of the MobileNet-v2, allows to better align the features of the two domain distributions and to further improve the performance. Finally, the consistency of the semantic maps is exploited. After an initial supervised training on synthetic data, the whole UDA architecture is trained end-to-end considering all its components at once. Experimental results show how the proposed strategy is able to obtain impressive performance in adapting a segmentation network trained on synthetic data to real world scenarios. The usage of the lightweight MobileNet-v2 architecture allows its deployment on devices with limited computational resources as the ones employed in autonomous vehicles

COVID-19 outbreak in healthcare workers in hospitals in Trieste, North-east Italy

N/

Antiblastic Treatment, for Solid Tumors, during Pregnancy: A Crucial Decision:

Cancer is the second leading cause of death during the reproductive years complicating between 0.02% and 0.1% of pregnancies. The incidence is expected to rise with the increase in age of childbearing. The most common types of pregnancy-associated cancers are: cervical cancer, breast cancer, malignant melanoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma and ovarian cancer. The relatively rare occurrence of pregnancy-associated cancer precludes conducting large, prospective studies to examine diagnostic, management and outcome issues. The treatment of pregnancy-associated cancer is complex since it may be associated with adverse fatal effects. In pregnant patients diagnosed with cancer during the first trimester, treatment with multidrug anti-cancer chemotherapy is associated with an increased risk of congenital malformations, spontaneous abortions or fetal death, and therefore, should follow a strong recommendation for pregnancy termination. Second and third trimester exposure is not associated with teratogenic effect but increases the risk of intrauterine growth retardation and low birth weight. There are no sufficient data regarding the teratogenicity of most cytotoxic drugs. Almost all chemotherapeutic agents were found to be teratogenic in animals and for some drugs only experimental data exist. Moreover, no pharmacokinetic studies have been conducted in pregnant women receiving chemotherapy in order to understand whether pregnant women should be treated with different doses of chemotherapy. This article reviews the available data regarding the different aspects of the treatment of cancer during pregnancy

Gender Asymmetry in Okun's Law in the Four PIGS Countries

AbstractCentred on the four PIGS countries (Portugal, Italy, Greece and Spain) and using the quarterly data from Q2/1998 until Q4/2014, the paper investigates whether there exists gender asymmetries in Okun's law and whether male unemployment reacts identically to economic fluctuations as female unemployment does. Whilst the trend components of output, male and female unemployment are estimated with the aid of the HP filter, Okun's relationships are modelled in the SVAR framework assuming that cyclical fluctuations of the economy and the labour market with both male and female labour force are endogenous. It is established that gender is indeed a factor that makes the respective segments of the labour market respond slightly differently to changes in real output

Eruption type probability and eruption source parameters at Cotopaxi and Guagua Pichincha volcanoes (Ecuador) with uncertainty quantification

Future occurrence of explosive eruptive activity at Cotopaxi and Guagua Pichincha volcanoes, Ecuador, is assessed probabilistically, utilizing expert elicitation. Eight eruption types were considered for each volcano. Type event probabilities were evaluated for the next eruption at each volcano and for at least one of each type within the next 100 years. For each type, we elicited relevant eruption source parameters (duration, average plume height, and total tephra mass). We investigated the robustness of these elicited evaluations by deriving probability uncertainties using three expert scoring methods. For Cotopaxi, we considered both rhyolitic and andesitic magmas. Elicitation findings indicate that the most probable next eruption type is an andesitic hydrovolcanic/ash-emission (~ 26–44% median probability), which has also the highest median probability of recurring over the next 100 years. However, for the next eruption at Cotopaxi, the average joint probabilities for sub-Plinian or Plinian type eruption is of order 30–40%—a significant chance of a violent explosive event. It is inferred that any Cotopaxi rhyolitic eruption could involve a longer duration and greater erupted mass than an andesitic event, likely producing a prolonged emergency. For Guagua Pichincha, future eruption types are expected to be andesitic/dacitic, and a vulcanian event is judged most probable for the next eruption (median probability ~40–55%); this type is expected to be most frequent over the next 100 years, too. However, there is a substantial probability (possibly >40% in average) that the next eruption could be sub-Plinian or Plinian, with all that implies for hazard levels

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer

The aim of this study was to assess the association of p53 status with primary cytoreduction, response to chemotherapy and outcome in stage III–IV primary ovarian cancer patients. Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary ovarian carcinomas by using the DO-7 monoclonal antibody. p53 nuclear positivity was found in 84 out of 162 (52%) malignant tumours. A higher percentage of p53 nuclear positivity was observed in patients with advanced stage of disease than in stage I–II (57% vs 23% respectively; P = 0.0022) and in poorly differentiated versus well/moderately differentiated tumours (59% vs 32% respectively; P = 0.0038). The multivariate analysis aimed to investigate the association of FIGO stage, grade and p53 status with primary cytoreduction in 136 stage III–IV patients showed that stage IV disease may influence the possibility to perform primary cytoreduction in ovarian cancer patients. p53-positivity also maintained a trend to be associated with poor chance of cytoreduction. In patients who underwent pathologic assessment of response, cases who did not respond to chemotherapy were much more frequently p53-positive than p53-negative (86% vs 14% respectively; P = 0.012). Moreover, patients with stage III disease and < 2-cm residual tumour were more likely to respond to treatment. In multivariate analysis, FIGO stage and p53 expression were independently correlated with pathologic response to chemotherapy. Time to progression and survival rates were shown not to be different in p53-positive versus p53-negative patients. © 1999 Cancer Research Campaig

Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: A study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced germ cell tumors. Twenty European Society for Blood and Marrow Transplantation centers contributed data on patients treated between 2002 and 2012. Paclitaxel used in either prior lines of therapy or in induction-mobilization regimens was considered. Multivariable Cox analyses of prespecified factors were undertaken on PFS and overall survival (OS). As of October 2013, data for 324 patients had been contributed to this study. One hundred and ninety-two patients (59.3%) had received paclitaxel. Sixty-one patients (19%) had a progression to induction chemotherapy, 234 (72%) a response (29 (9%) missing or granulocyte colony-stimulating factor without chemotherapy). Both progression to induction chemotherapy and prior paclitaxel were significantly associated with shorter OS univariably (P&lt;0.001 and P=0.032). On multivariable analysis from the model with fully available data (N=216) progression to induction was significantly prognostic for PFS and OS (P=0.003), but prior paclitaxel was not (P=0.674 and P=0.739). These results were confirmed after multiple imputation of missing data. Progression to induction chemotherapy could be demonstrated as an independent prognostic factor, in contrast to prior paclitaxel